Cognition Therapeutics Stock (NASDAQ:CGTX)


ForecastOwnershipFinancialsChartTranscripts

Previous Close

$0.84

52W Range

$0.22 - $1.29

50D Avg

$0.42

200D Avg

$0.49

Market Cap

$44.33M

Avg Vol (3M)

$7.46M

Beta

0.87

Div Yield

-

CGTX Company Profile


Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Oct 08, 2021

Website

CGTX Performance


CGTX Financial Summary


Dec 24Dec 23Dec 22
Revenue---
Operating Income$-53.97M$-50.72M$-43.55M
Net Income$-33.97M$-25.79M$757.00K
EBITDA$-53.97M$-25.51M$-21.13M
Basic EPS$-0.86$-0.86$0.03
Diluted EPS$-0.86$-0.86$0.03

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q4 24Mar 20, 25 | 8:00 AM
Q1 24Aug 11, 24 | 8:30 AM
Q4 23Mar 26, 24 | 8:00 AM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
INABIN8bio, Inc.
RVPHReviva Pharmaceuticals Holdings, Inc.
ELEVElevation Oncology, Inc.
LTRNLantern Pharma Inc.
UNCYUnicycive Therapeutics, Inc.